Deciphera Historical Income Statement
| DCPH Stock | USD 25.58 0.01 0.04% |
Historical analysis of Deciphera Pharmaceuticals income statement accounts such as Interest Expense of 5.4 M or Selling General Administrative of 74.7 M can show how well Deciphera Pharmaceuticals LLC performed in making a profits. Evaluating Deciphera Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Deciphera Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Deciphera Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Deciphera Pharmaceuticals is a good buy for the upcoming year.
Deciphera |
About Deciphera Income Statement Analysis
Deciphera Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Deciphera Pharmaceuticals shareholders. The income statement also shows Deciphera investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Deciphera Pharmaceuticals Income Statement Chart
Add Fundamental
Interest Income
Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Deciphera Pharmaceuticals. It is also known as Deciphera Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Deciphera Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Deciphera Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Deciphera Pharmaceuticals LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. As of now, Deciphera Pharmaceuticals' Total Revenue is increasing as compared to previous years. The Deciphera Pharmaceuticals' current Gross Profit is estimated to increase to about 167.6 M, while Selling General Administrative is projected to decrease to under 74.7 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 3.0M | 2.9M | 2.1M | 3.0M | Interest Income | 113K | 4.5M | 13.9M | 14.6M |
Deciphera Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Deciphera Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Deciphera Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Income | 8.5M | 4.7M | 113K | 4.5M | 13.9M | 14.6M | |
| Depreciation And Amortization | 8.5M | 7.0M | 3.0M | 2.9M | 2.1M | 3.0M | |
| Interest Expense | 67K | 4.7M | 113K | 4.5M | 5.2M | 5.4M | |
| Selling General Administrative | 68.1M | 114.1M | 136.3M | 120.2M | 129.5M | 74.7M | |
| Total Revenue | 25M | 42.1M | 96.1M | 134.0M | 163.4M | 171.5M | |
| Gross Profit | 24.2M | 41.9M | 93.2M | 125.3M | 159.6M | 167.6M | |
| Other Operating Expenses | 225.7M | 313.3M | 396.2M | 316.8M | 374.3M | 223.0M | |
| Operating Income | (200.7M) | (271.2M) | (300.1M) | (182.7M) | (211.0M) | (221.5M) | |
| Net Income From Continuing Ops | (192.3M) | (266.5M) | (300.0M) | (178.9M) | (193.7M) | (203.4M) | |
| Ebit | (200.7M) | (271.2M) | (300.1M) | (182.7M) | (211.0M) | (221.5M) | |
| Research Development | 157.6M | 199.0M | 257.0M | 187.8M | 234.1M | 145.5M | |
| Ebitda | (192.2M) | (264.2M) | (297.1M) | (179.8M) | (211.0M) | (221.5M) | |
| Cost Of Revenue | 830K | 225K | 2.9M | 8.8M | 3.7M | 2.0M | |
| Total Operating Expenses | 225.7M | 313.1M | 393.3M | 308.0M | 370.6M | 221.1M | |
| Income Before Tax | (192.3M) | (266.5M) | (300.0M) | (178.2M) | (194.5M) | (204.2M) | |
| Total Other Income Expense Net | 8.5M | 4.7M | 113K | 4.5M | 16.4M | 17.3M | |
| Net Income Applicable To Common Shares | (192.3M) | (266.5M) | (300.0M) | (178.9M) | (161.0M) | (169.1M) | |
| Net Income | (191.5M) | (266.5M) | (296.8M) | (178.9M) | (194.9M) | (204.7M) | |
| Income Tax Expense | (763K) | (4.7M) | (3.1M) | 722K | 431K | 452.6K | |
| Net Interest Income | 8.5M | 4.7M | 113K | 4.5M | 13.9M | 14.6M | |
| Reconciled Depreciation | 830K | 2.3M | 3.0M | 2.9M | 2.2M | 1.9M | |
| Non Operating Income Net Other | 8.5M | 4.7M | 113K | 4.5M | 5.2M | 4.2M |
Currently Active Assets on Macroaxis
| COST | Costco Wholesale Corp | |
| AMZN | Amazon Inc | |
| AVGO | Broadcom | |
| META | Meta Platforms | |
| ADBE | Adobe Systems Incorporated |
Additional Information and Resources on Investing in Deciphera Stock
When determining whether Deciphera Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Deciphera Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Deciphera Pharmaceuticals Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Deciphera Pharmaceuticals Llc Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Deciphera Pharmaceuticals LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Deciphera Pharmaceuticals. If investors know Deciphera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Deciphera Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.21) | Revenue Per Share 2.028 | Quarterly Revenue Growth 0.345 | Return On Assets (0.27) | Return On Equity (0.50) |
The market value of Deciphera Pharmaceuticals is measured differently than its book value, which is the value of Deciphera that is recorded on the company's balance sheet. Investors also form their own opinion of Deciphera Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Deciphera Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Deciphera Pharmaceuticals' market value can be influenced by many factors that don't directly affect Deciphera Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Deciphera Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Deciphera Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Deciphera Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.